Docetaxel: A Review of its Pharmacodynamic and Pharmacokinetic Properties and Therapeutic Efficacy in the Management of Metastatic Breast Cancer

Drugs

Volumn 51, Issue 6, 1996, Pages 1075-1092

  Fulton, Bret ^a   Spencer, Caroline M ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DOCETAXEL;

ALOPECIA; ANTINEOPLASTIC ACTIVITY; ASTHENIA; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DESQUAMATION; DIARRHEA; DRUG ABSORPTION; DRUG CYTOTOXICITY; DRUG ELIMINATION; DRUG MECHANISM; DRUG METABOLISM; FLUID RETENTION; HUMAN; HYPERSENSITIVITY; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; META ANALYSIS; METASTASIS; MICROTUBULE ASSEMBLY; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; RASH; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; CLINICAL TRIALS; HUMANS; PACLITAXEL; TAXOIDS;

EID: 0030009814     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199651060-00011     Document Type: Article

References (86)

1. Gelmon K. The taxoids: paclitaxel and docetaxel. Lancet 1994 Nov 5; 344: 1267-72
2. Kaye SB. Taxoids. Eur J Cancer A 1995; 31A (5): 824-6
3. Bissery M-C, Nohynek G, Sanderink G-J, et al. Docetaxel (Taxotere®): a review of preclinical and clinical experience. Part 1: preclinical experience. Anticancer Drugs 1995 Jun; 6: 339-68
4. Spencer CM, Faulds D. Paclitaxel: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of cancer. Drugs 1994 Nov; 48 (5): 794-847
5. Ringle I, Horwitz SB. Studies with RP56976 (taxotere): a semi-synthetic analogue of taxol. J Natl Cancer Inst 1991 Feb 20; 83: 288-91
6. Diaz JF, Andreu JM. Assembly of purified GDP-tubulin into microtubules induced by Taxol and Taxotere: reversibility, ligand stoichiometry, and competition. Biochemistry 1993 Mar 23; 32: 2747-55
7. Kumar N. Taxol-induced polymerization of purified tubulin. J Biol Chem 1981; 256: 10435-41
8. Andreu JM, Diaz JF, Gil R, et al. Solution structure of Taxotere-induced microtubules to 3-nm resolution. The change in protofilament number is linked to the binding of the taxol side chain. J Biol Chem 1994 Dec 16; 269: 31785-92
9. Fromes Y, Gounon P, Bissery MC, et al. Differential effects of Taxol and Taxotere (RP56976, NSC628503) on Tau and MAP2containing microtubules [abstract no. 3055]. Proceedings of the American Association Cancer Research 1992; 33: 511
10. Hennequin C, Giocanti N, Favaudon V. S-phase specificity of cell killing by docetaxel (Taxotere) in synchronised HeLa cells. Br J Cancer 1995 Jun; 71: 1194-8
11. Vogel M, Hilsenbeck SG, Depenbrock H, et al. Preclinical activity of taxotere (RP 56976, NSC 628503) against freshly explanted clonogenic human tumour cells: comparison with taxol and conventional antineoplastic agents. Eur J Cancer A 1993; 29A (14): 2009-14
12. Hanauske A-R, Degen D, Hilsenbeck S-G, et al. Effects of Taxotere and taxol on in vitro colony formation of freshly explanted human tumor cells. Anticancer Drugs 1992 Apr; 3: 121-4
13. Hill BT, Whelan RDH, Shellard SA, et al. Differential cytotoxic effects of docetaxel in a range of mammalian tumor cell lines and certain drug resistant sublines in vitro. Invest New Drugs 1994; 12(3): 169-82
14. Riou J-F, Naudin A, Lavelle F. Effects of taxotere on murine and human tumor cell lines. Biochem Biophys Res Commun 1992 Aug 31; 187: 164-70
15. Untch M, Untch A, Sevin B-U, et al. Comparison of paclitaxel and docetaxel (Taxotere) in gynecologic and breast cancer cell lines with the ATP-cell viability assay. Anticancer Drugs 1994 Feb; 5: 24-30
16. Braakhuis BJM, Hill BT, Dietel M, et al. In vitro antiproliferative activity of docetaxel (Taxotere®), paclitaxel (Taxol) and cisplatin against human tumour and normal bone marrow cells [abstract no. 149-0348]. Anticancer Res 1994 Jan-Feb; 14: 205-8
17. Zoli W, Flamigni A, Frassineti GL, et al. In vitro activity of taxol and taxotere in comparison with doxorubicin and cisplatin on primary cell cultures of human breast cancers. Breast Cancer Res Treat 1995 Apr; 34: 63-9
18. Kelland LR, Abel G. Comparative in vitro cytotoxicity of taxol and Taxotere against cisplatin-sensitive and -resistant human ovarian carcinoma cell lines. Cancer Chemother Pharmacol 1992 Sep; 30: 444-50
19. Bissery MC, Vrignaud P, Bayssas M, et al. Docetaxel (RP 56976, Taxotere®) efficacy as a single agent or in combination against mammary tumors in mice [abstract no. 1946]. Proceedings of the American Association Cancer Research 1994 Mar; 35: 327
20. Bissery M-C, Guénard D, Guéritte-Voegelein F, et al. Experimental antitumor activity of Taxotere (RP 56976, NSC 628503), a taxol analogue. Cancer Res 1991 Sep 15; 51: 4845-52
21. Dykes DJ, Bissery MC, Harrison Jr. SD, et al. Response of human tumor xenografts in athymic nude mice to docetaxel (RP56976, Taxotere®). Invest New Drugs 1995; 13: 1-11
22. Lavelle F, Bissery MC, Riou JF, et al. Preclinical evaluation of docetaxel (Taxotere). Semin Oncol 1995 Apr; 22 Suppl. 4: 3-16
23. Riou JF, Petitgenet O, Aynie I, et al. Establishment and characterization of docetaxel (Taxotere®) resistant human breast carcinoma (Calc18/TXT) and murine leukemic(P388/TXT) cell lines. Proceedings of the American Association Cancer Research 1994; 35: 399
24. Chou T-C, Otter GM, Sirotnak FM. Schedule-dependent synergism of taxol or taxotere with edatrexate against human breast cancer cells in vitro. Cancer Chemother Pharmacol 1996; 37: 222-8
25. Bissery MC, Vrignaud P, Bayssas M, et al. Taxotere® synergistic combination with cyclophosphamide, etoposide and 5-fluorouracil in mouse tumor models. Proceedings of the American Association Cancer Research 1993; 34: 299
26. Manthey CL, Qureshi N, Stutz PL, et al. Lipopolysaccharide antagonists block Taxol-induced signaling in murine macrophages. J Exp Med 1993 Aug 1; 178: 695-702
27. Burkhart CA, Berman JW, Swindell CS, et al. Relationship between the structure of taxol and other taxanes on induction of tumor necrosis factor-α gene expression and cytotoxicity. Cancer Res 1994 Nov 15; 54: 5779-82
28. Choy H, Rodriguez F, Wilcox B, et al. Radiation sensitizing effects of Taxotere® (RP 56976) [abstract no. 2991]. Proceedings of the American Association Cancer Research 1992; 33: 500
29. Aapro MS, Zulian G, Alberto P, et al. Phase I and pharmacokinetic study of RP 56976 in a new ethanol-free formulation of taxotere [abstract no. 208]. Ann Oncol 1992; 3 Suppl. 5: 53
30. Burris H, Irvin R, Kuhn J, et al. Phase I clinical trial of taxotere administered as either a 2-hour or 6-hour intravenous infusion. J Clin Oncol 1993 May; 11: 950-8
31. Extra J-M, Rousseau F, Bruno R, et al. Phase I and pharmacokinetic study of taxotere (RP 56976; NSC 628503) given as a short intravenous infusion. Cancer Res 1993 Mar 1; 53: 1037-42
32. Rhône-Poulenc Rorer. Docetaxel product monograph. 2nd edition, 1996.
33. Launay-Iliadis MC, Bruno R, Cosson V, et al. Population pharmacokinetics of docetaxel during phase I studies using nonlinear mixed-effect modeling and nonparametric maximum-likelihood estimation. Cancer Chemother Pharmacol 1995; 37: 47-54
34. Marre F, De Sousa G, Placidi M, et al. Élucidation des voies de biotransformation hépatique du Taxotère au moyen de modèles in vitro d'origine humaine [abstract]. Bull Cancer 1993; 80 (6): 527
35. Commerçon A, Bourzat J-D, Bézard J-D, et al. Partial synthesis of major human metabolites of docetaxel. Tetrahedron 1994; 50 (34): 10289-98
36. Bruno R, Sanderink GJ. Pharmacokinetics and metabolism of Taxotere™ (docetaxel). Cancer Surv 1993; 17: 305-13
37. 14 radiolabelled Taxotere (TXT) (RP56976, NSC628503) in cancer patients [abstract no. 2221]. Proceedings of the American Association Cancer Research 1993 March; 34: 373
38. Royer I, Monsarrat B, Sonnier M, et al. Metabolism of docetaxel by human cytochromes P450: interactions with paclitaxel and other antineoplastic drugs. Cancer Res 1996; 56: 58-65
39. Schellens JHM, Ma J, Bruno R, et al. Pharmacokinetics of cisplatin and Taxotere® (docetaxel) and WBC DNA-adduct formation of cisplatin in the sequence Taxotere®/cisplatin and cisplatin/Taxotere® in a phase I/II study in solid tumor patients [abstract]. Proc Am Soc Clin Oncol 1994 Mar; 13: 132
40. Bissett D, Setanoians A, Cassidy J, et al. Phase I and pharmacokinetic study of taxotere (RP 56976) administered as a 24-hour infusion. Cancer Res 1993 Feb 1; 53: 523-7
41. Pazdur R, Newman RA, Newman BM, et al. Phase I trial of Taxotere: five-day schedule. J Natl Cancer Inst 1992 Dec 2; 84: 1781-8
42. Tomiak E, Piccart MJ, Kerger J, et al. Phase I study of docetaxel administered as a 1-hour intravenous infusion on a weekly basis. J Clin Oncol 1994 Jul; 12: 1458-67
43. Taguchi T, Furue H, Niitani H, et al. Phase I clinical trial of RP56976 (docetaxel) a new anticancer drug [in Japanese]. Gan to Kagaku Ryoho 1994 Sep; 21: 1997-2005
44. Miller AB, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment. Cancer 1981 Jan; 47: 207-14
45. Chevallier B, Fumoleau P, Kerbrat P, et al. Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer. J Clin Oncol 1995 Feb; 13: 314-22
46. 2 as first-line chemotherapy for patients with advanced breast cancer: report of the Clinical Screening Group of the EORTC. Br J Cancer. In press.
47. Fumoleau P, Chevallier B, Kerbrat P, et al. A multicentre phase II study of the efficacy and safety of docetaxel as first-line treatment of advanced breast cancer: Report of the Clinical Screening Group of the EORTC. Ann Oncol In press
48. Hudis CA, Seidman AD, Crown JPA, et al. Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer. J Clin Oncol 1996 Jan; 14(1): 58-65
49. Trudeau ME, Eisenhauer EA, Higgins BP, et al. Docetaxel in patients with metastatic breast cancer: a phase II study of the National Cancer Institute of Canada-Clinical Trials Group. J Clin Oncol 1996 Feb; 14 (2): 422-8
50. Dieras V, Fumoleau P, Chevallier B, et al. Second EORTC-Clinical Screening Group (CSG) phase II trial of Taxotere® (docetaxel) as first line chemotherapy in advanced breast cancer (ABC) [abstract]. Proc Am Soc Clin Oncol 1994 Mar; 13: 78
51. Ravdin PM, Burris III HA, Cook G, et al. Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer. J Clin Oncol 1995 Dec; 13 (12): 2879-85
52. ten Bokkel Huinink WW, Prove AM, Piccart M, et al. A phase II trial with docetaxel (Taxotere®) in second line treatment with chemotherapy for advanced breast cancer: a study of the EORTC Early Clinical Trials Group. Ann Oncol 1994 Jul; 5: 527-32
53. Valero V, Holmes FA, Walters RS, et al. Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracyclin-resistant metastatic breast cancer. J Clin Oncol 1995 Dec; 13(12): 2886-94
54. Bellet R, Riva A, Ravdin P, et al. Docetaxel (Taxotere): a new active agent in antracycline resistant metastatic breast cancer. Rhône-Poulenc Rorer (data on file).
55. Adachi I, Watanabe T, Takashima S, et al. A late phase II study of RP56976 (docetaxel) in patients with advanced or recurrent breast cancer. Br J Cancer 1996; 73: 210-6
56. Taguchi T. An early phase II clinical study of RP56976 (docetaxel) in patients with cancer of the gastrointestinal tract [in Japanese]. Can to Kagaku Ryoho 1994 Oct; 21: 2431-7
57. Taguchi T, Mori S, Abe R, et al. Late phase II clinical study of RP56976 (docetaxel) in patients with advanced/recurrent breast cancer [in Japanese]. Gan to Kagaku Ryoho 1994 Nov; 21: 2625-32
58. Mouridsen HT. Systemic therapy of advanced breast cancer Drugs 1992; 44Suppl 4: 17-28
59. Gruia G, Misset JL, Giachetti S, et al. A phase I-II study of Taxotere (TXTR) in combination with Adriamycin (AD) as first line chemotherapy (CT) in patients with metastatic breast cancer [abstract no. 258]. Proc Am Soc Clin Oncol 1995; 14: 140
60. Zalcberg J, Bishop JF, Webster LK, et al. A phase I trial of the combination Taxotere (docetaxel) and cisplatin in patients with advanced non-small cell lung cancer (NSCLC) [abstract no. P773]. Ann Oncol 1994; 5 Suppl. 8: 154
61. Cole JT, Gralla RJ, Marques CB, et al. Phase I-II study of cisplatin + docetaxel (Taxotere) in non-small cell lung cancer (NSCLC) [abstract no. 1087]. Proc Am Soc Clin Oncol 1995; 14: 357
62. Verweij J, Planting AST, van der Burg MEL, et al. A phase I study of docetaxel (Taxotere) and cisplatin in patients with solid tumors [abstract no. 386]. Proc Am Soc Clin Oncol 1994 Mar; 13: 148
63. Burris III HA, Fields S, Peacock N. Docetaxel (Taxotere) in combination: a step forward. Semin Oncol 1995 Dec; 95 (22) Suppl. 6: 35-40
64. Cortes JE, Pazdur R. Docetaxel. J Clin Oncol 1995 Oct; 13: 2643-55
65. Fumoleau P, Chevallier B, Dieras V, et al. Safety evaluation of two doses of Taxotere® (docetaxel) without routine premedication as first line in advanced breast cancer (ABC)-EORTC Clinical Screening Group (CSG) report [abstract]. Proc Am Soc Clin Oncol 1994 Mar; 13: 109
66. Van Oosterom AT, Schriivers D. Docetaxel (Taxotere®), a review of preclinical and clinical experience. Part II: clinical experience. Anticancer Drugs 1995 Jun; 6: 356-68
67. Jaffrézou J-P, Laurent G. Docetaxel (Taxotere): current status and clinical prospects. Expert Opin Invest Drug 1995 Dec; 4 (12): 1185-95
68. Tomiak E, Kerger J, Lips S, et al. Unexpected pleural changes observed in patients treated with Taxotere (RP56976): a new drug toxicity? [abstract]. Ann Oncol 1992 Nov; 3 Suppl. 5: 48
69. Piccart MJ, Klijn J, Paridaens R, et al. Steroids do reduce the severity and delay the onset of docetaxel (DXT) induced fluid retention: final results of a randomized trial of the EORTC investigational drug branch for breast cancer (IDBBC) [abstract]. Eur J Cancer 1995 Nov; 31A Suppl. 5: S75
70. Oulid-Aïssa D, Béhar A, Spielmann M, et al. Management of fluid retention syndrome in patients treated with Taxotere® (docetaxel): effect of premedication [abstract]. Proc Am Soc Clin Oncol 1994 Mar; 13: 465
71. Balmaceda C, Forsyth P, Seidman AD, et al. Peripheral neuropathy in patients receiving taxotere chemotherapy [abstract]. Ann Neurol 1993 Aug; 34: 313
72. New PZ, Barohn R. Neurotoxicity of Taxotere [abstract]. Neurology 1993 Apr; 43 Suppl. 2: A191
73. Van den Bent MJ, Hilkens PHE, Verwey J, et al. Docetaxel induces a mild dose-dependent sensory neuropathy [abstract]. Neurology 1995 Apr; 45 Suppl. 4: 322
74. Hilkens PHE, Verweij J, Stoter G, et al. Peripheral neurotoxicity induced by docetaxel. Neurology 1996 Jan; 46: 104-8
75. Cavaletti G, Tredici G. Platinum compounds and taxoids: is combination neurotoxicity a possibility? Cancer J 1995 Mar-Apr; 8: 46-7
76. Wanders J, Schrijvers D, Bruntsch U, et al. The EORTC-ECTG experience with acute hypersensitivity reactions in Taxotere studies [abstract]. Proc Am Soc Clin Oncol 1993 Mar; 12: 73
77. Eisenhauer EA, Lu F, Muldal A, et al. Predictors and treatment of docetaxel (D) toxic effects [abstract]. Ann Oncol 1994; 5 Suppl. 5: 202
78. Wanders J, Van Oosterom A, Gore M, et al. Taxotere toxicity - protective effects of premedication [abstract no. S206]. Eur J Cancer 1993; 29A Suppl. 6: 1148
79. Zimmerman GC, Keeling JH, Burris HA, et al. Acute cutaneous reactions to docetaxel, a new chemotherapeutic agent. Arch Dermatol 1995 Feb; 131: 202-6
80. Battafarano DF, Zimmerman GC, Older SA, et al. Docetaxel (Taxotere) associated scleroderma-like changes of the lower extremities: a report of three cases. Cancer 1995 Jul 1; 76: 110-5
81. Harris JR, Lippman ME, Veronesi U, et al. Breast cancer (first of three parts). N Engl J Med 1992 July 30; 327 (5): 319-28
82. McPherson K, Steel CM, Dixon JM. Breast cancer-epidemiology, risk factors, and genetics. BMJ 1994 Oct 15; 309: 1003-6
83. Early Breast Cancer Trialist's Collaborative Group. Syterosis treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31 000 recurrances and 24 000 deaths among 75 000 women. Lancet 1992; 339: 1-15, 71-85
84. Sledge Jr GW, Amman KM. Progress in chemotherapy for metastatic breast cancer. Semin Oncol 1992 June; 19 (3): 317-32
85. Rubens RD. Improving treatment for advanced breast cancer. Cancer Surv 1993; 18: 199-208
86. Hutton J, Brown R, Borowitz M, et al. A new decision model for cost-utility comparisons of chemotherapy in recurrent metastatic breast cancer. PharmacoEconomics. In press